IRCT20150221021159N7 IRCT 2021-11-10 Esfahan University of Medical Sciences Effect of Atorvastatin in the management of COVID-19 Evaluation of the efficacy of Atorvastatin in the management of critically ill COVID-19 patients: A Randomized-controlled clinical trial 2021-10-23 anticipated 60 Complete https://irct.ir/trial/58978 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization with the permuted block method was used to create the random sequence in each group. At first, the specific internet software (https://www.sealedenvelope.com/simple-randomiser/v1/lists) was used to create the random series in blocks of 2, 4, and 6. Each block has an equal number of melatonin and control groups. After that, created codes were written on the cards and placed respectively for hiding in locked opaque packets. A packet was selected for each patient according to the study recruitment, which determines the related study group. 3 COVID-19. Intervention 1: Intervention group: In addition to the essential and standard treatment for COVID-19, one tablet of atorvastatin 20 mg (Abidi pharmaceutical company), once daily will be administered for 14 days. Intervention 2: Control group: Standard and essential treatment for COVID-19. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.